Clinical Trials - Washington
-
A5345, Identification of Biomarkers to Predict Time to Plasma HIV RNA Rebound and Post-Treatment Viral Control during an Intensively Monitored Antiretroviral Pause
Study Location: Washington
Eligibility: HIV-infected men and women ≥18 to ≤70 years of age, maintained on suppressive ART for a minimum of 2 years with CD4+ count...
Enrollment: Open
-
A5354/EARLIER: Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection . . . Effect of Antiretroviral Treatment Initiated During Acute HIV-1 Infection on Measures of HIV-1 Persistence and on HIV-1-Specific Immune Responses
Study Location: Washington
Eligibility: Men and women who: Are at least 18 years old Have had certain lab tests done that confirm very early HIV infection Are...
Enrollment: Open
-
A5128: Consent for Use of Stored Patient Specimens for Future Testing
Study Location: BaltimoreWashington
Eligibility: Genders Eligible for Study: Both Accepts Healthy Volunteers: Yes Sampling Method: Non-Probability Sample...
Enrollment: Open
-
A5346: Sitagliptin for Reducing Inflammation and Immune Activation
Study Location: Washington
Eligibility: Ages Eligible for Study: 18 Years and older Genders Eligible for Study: Both Accepts Healthy Volunteers: ...
Enrollment: Closed
-
A5337: Safety and Efficacy of Sirolimus for HIV Reservoir Reduction in Individuals on Suppressive Antiretroviral Therapy
Study Location: Washington
Eligibility: HIV-infected men and woman, at least 18 years of age Taking anti-HIV medications that have controlled the HIV viral load...
Enrollment: Open
-
A5332: Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE)
Study Location: BaltimoreIndiaWashington
Eligibility: HIV infected men and women between the ages of 40 and 75 On HIV medications for at least 6 months CD4 cell count greater...
Enrollment: Open
-
A5308: A Prospective, Single-Arm, Open-Label Study to Evaluate the Effect of Fixed-Dose Emtricitabine/Rilpivirine/Tenofovir Disoproxil Fumarate on T-Cell Activation, Absolute CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir in Treatment-Naïve HIV-1 Controllers
Study Location: Washington
Eligibility: Enrollment is closed.
Enrollment: Closed
-
A5327: Sofosbuvir + Ribavirin w/o Interferon for Treatment of Acute HCV in HIV-1 Infected Individuals (SWIFT-C)
Study Location: BaltimoreWashington
Eligibility: Men and women > 18 years, HIV+ and currently on stable antiretroviral (ARV) medications or on for at least 8 weeks and be...
Enrollment: Closed
-
A5324: A Randomized, Double-Blinded, Placebo-Controlled Trial Comparing Antiretroviral Intensification with Maraviroc and Dolutegravir with No Intensification or Intensification with Dolutegravir Alone for the Treatment of Cognitive Impairment in HIV
Study Location: BaltimoreWashington
Eligibility: Men and women > 18 years old who have HIV-associated neurocognitive disorder (HAND) as defined by the Frascati...
Enrollment: Open
-
A5320: Viral Hepatitis C Infection Long-term Cohort Study (V-HICS)
Study Location: BaltimoreWashington
Eligibility: Men and women ≥ 18 years old, HCV/HIV-1 coinfected who failed HCV therapy any time after HCV/DAA treatment discontinuation...
Enrollment: Open